Zengke Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zengke Chen has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Dorothy C. C. Wai
Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville 3052, Victoria, Australia
2 shared publications - Gyorgy Panyi
Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen and MTA Centre of Excellence, Hungarian Academy of Sciences, Egyetem tér 1, Debrecen H-4032, Hungary
2 shared publications Hefeng Song
Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville 3052, Victoria, Australia
2 shared publications- Jinghan Qu
Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville 3052, Victoria, Australia
2 shared publications - Karoline Sanches
Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville 3052, Victoria, Australia
2 shared publications - Lihuan Lin
Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville 3052, Victoria, Australia
2 shared publications
Latest Publications
- Open Access
- 16 July 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 702, 127198
Lipidation of the KV1.3 blocking peptide HsTX1[R14A] alters its pharmacokinetics and biodistribution
- 16 July 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 702, 127198
Open AccessLipidation of the KV1.3 blocking peptide HsTX1[R14A] alters its pharmacokinetics and biodistribution
- Open Access
- 1 April 2026
- Published by Elsevier in SSRN Electronic Journal
Lipidation of the KV1.3 blocking peptide HsTX1[R14A] alters its pharmacokinetics and biodistribution
Autoimmune diseases impact over 250 million people globally. Previous studies have shown that upregulation of the voltage-gated potassium channel KV1.3 in effector memory T cells is associated with the pathogenesis of a range of autoimmune diseases. HsTX1[R14A] is a 34-residue peptide that has picomolar potency and high selectivity for KV1.3, and is effective in treating a rodent model of rheumatoid arthritis. However, the short in vivo half-life of HsTX1[R14A] can be improved to enhance its potential as a therapeutic candidate. Here we explore how lipid conjugation on HsTX1[R14A] affects its circulating half-life and its distribution to key organs, tissues, and draining lymph nodes. HsTX1[R14A] was conjugated to lipids with long acyl chain (C16 and C18) for pharmacokinetic (PK) studies, and the fluorophore Cy5 was conjugated to the HsTX1[R14A] analogs for biodistribution studies. LC-MS/MS assays were developed to quantify the lipidated peptides in mouse plasma. Conjugation of palmitic and stearic acid to HsTX1[R14A] extended its exposure in plasma by 9-fold and prolonged its half-life by 2-fold after subcutaneous (SC) injection in mice. Biodistribution studies demonstrated that Cy5-labelled lipidated analogs enhance accumulation at the dosing site and draining lymph nodes at 4 h and 12 h after SC injection compared to Cy5-HsTX1[R14A]. Cy5-labelled lipidated analogues of HsTX1[R14A] also accumulated in the gastrointestinal (GI) tract more than HsTX1[R14A], while having significantly less exposure in the kidneys at 4 h and 12 h after SC administration. Thus, lipidation is a promising approach to optimize the PK, biodistribution and therapeutic potential of HsTX1[R14A].
- 1 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessLipidation of the KV1.3 blocking peptide HsTX1[R14A] alters its pharmacokinetics and biodistribution
Autoimmune diseases impact over 250 million people globally. Previous studies have shown that upregulation of the voltage-gated potassium channel KV1.3 in effector memory T cells is associated with the pathogenesis of a range of autoimmune diseases. HsTX1[R14A] is a 34-residue peptide that has picomolar potency and high selectivity for KV1.3, and is effective in treating a rodent model of rheumatoid arthritis. However, the short in vivo half-life of HsTX1[R14A] can be improved to enhance its potential as a therapeutic candidate. Here we explore how lipid conjugation on HsTX1[R14A] affects its circulating half-life and its distribution to key organs, tissues, and draining lymph nodes. HsTX1[R14A] was conjugated to lipids with long acyl chain (C16 and C18) for pharmacokinetic (PK) studies, and the fluorophore Cy5 was conjugated to the HsTX1[R14A] analogs for biodistribution studies. LC-MS/MS assays were developed to quantify the lipidated peptides in mouse plasma. Conjugation of palmitic and stearic acid to HsTX1[R14A] extended its exposure in plasma by 9-fold and prolonged its half-life by 2-fold after subcutaneous (SC) injection in mice. Biodistribution studies demonstrated that Cy5-labelled lipidated analogs enhance accumulation at the dosing site and draining lymph nodes at 4 h and 12 h after SC injection compared to Cy5-HsTX1[R14A]. Cy5-labelled lipidated analogues of HsTX1[R14A] also accumulated in the gastrointestinal (GI) tract more than HsTX1[R14A], while having significantly less exposure in the kidneys at 4 h and 12 h after SC administration. Thus, lipidation is a promising approach to optimize the PK, biodistribution and therapeutic potential of HsTX1[R14A].